Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

✍ Scribed by Keystone, E. (author);Emery, P. (author);Peterfy, C. G. (author);Tak, P. P. (author);Cohen, S. (author);Genovese, M. C. (author);Dougados, M. (author);Burmester, G. R. (author);Greenwald, M. (author);Kvien, T. K. (author);Illiams, S. (author);Hagerty, D. (author);Cravets, M. W. (author);Shaw, T. (author)

• Book ID: 119973957
• Publisher: BMJ Publishing Group
• Year: 2008
• Tongue: English
• Weight: 395 KB
• Volume: 68
• Category: Article
• ISSN: 0003-4967
• DOI: 10.1136/ard.2007.085787